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Purpose: KAI1 COOH-terminal interacting tetraspanin (KITENIN) has been found 
to act as a promoter of metastasis in murine models of colon cancer and squamous 
cell carcinoma (SCC). The suppression of tumor progression and metastasis of es-
tablished colon cancer in mice was observed after intravenous delivery of small in-
terfering RNA (siRNA) targeting KITENIN. The purpose of this study was to inves-
tigate the efficacy of gene therapy targeting KITENIN in human head and neck 
SCC. Materials and Methods: SNU-1041, a well-established human hypopharyn-
geal SCC cell line, was used. KITENIN expression in SNU-1041 was measured by 
Western blot analysis. The cells were prepared, maintained in culture dishes with 
media, and divided into two groups: the si-KITENIN group and the scrambled group 
(control). The siRNA targeting KITENIN (si-KITENIN) and scrambled DNA were 
transfected into the SNU-1041 cells in each group. The effect of gene therapy was 
compared by in vitro experiments to evaluate invasion, migration, and proliferation. 
Results: KITENIN was strongly expressed in the SNU-1041 cells, and the number 
of invaded cells was reduced more in the si-KITENIN group than in the scrambled 
group (p<0.001). The speed for the narrowing gap, made through adherent cells, was 
lower in the si-KITENIN group (p<0.001), and the number of viable proliferating 
cells was reduced in the si-KITENIN group compared to the scrambled group (p< 
0.001, the third day). KITENIN protein expression was no longer identified in the si-
KITENIN group. Conclusion: Gene therapy using an anti-KITENIN strategy might 
be effective for head and neck squamous carcinoma.
Key Words:    Gene therapy, head and neck cancer, squamous cell carcinoma, KIT-
ENIN protein, small interfering RNA (siRNA)
INTRODUCTION
Reducing the progression and metastasis of head and neck squamous cell carcino-
ma (SCC) requires an understanding of molecular mechanisms involved in inva-Joon Kyoo Lee, et al.
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as gene-coding siRNAs. Recent studies have demonstrated 
the general application of siRNAs to silence gene expres-
sion in a range of cell types and in mammalian models.16
The purpose of this study was to investigate the efficacy 
of gene therapy (siRNA targeting KITENIN) in human 
head and neck SCC.
MATERIALS AND METHODS
Cell culture and transfection
SNU-1041 cells,17-19 a well-established human head and neck 
SCC cell line, were grown in Dulbecco’s modified Eagle’s 
medium (DMEM, Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% fetal bovine serum (Hyclone, Logan, UT, 
USA) in a humidified atmosphere of 5% CO2 at 37°C. The 
cells were prepared and maintained in culture dishes with 
media, and divided into two groups: the si-KITENIN group 
and the scrambled group (control). The siRNA targeting KIT-
ENIN (si-KITENIN) and the scrambled DNA were transfect-
ed into the SNU-1041 cells in each group. The sequence of 
siRNA was as follows: human KITENIN 5’-GCUUG-
GACUUCAGCCUCGUAGUCAA-3’. The transfections 
were performed using the Lipofectamine RNAiMAX (Invit-
rogen) according to the manufacturer’s instructions. The cells 
were maintained and used for further analysis.
Western blot analysis
Western blot analysis was used to investigate KITENIN ex-
pression before and after transfection of siRNA (si-KIT-
ENIN). The tissues were solubilized in NP40 lysis buffer 
containing a protease inhibitor mixture (Roche, Indianapo-
lis, IN) and 1 mM phenylmethylsulfonyl fluoride. The re-
solved proteins (50 µg) were transferred to a nitrocellulose 
membrane and blotted with the KITENIN antibody and an-
tirabbit immunoglobulin-horseradish peroxidase (Amer-
sham, Arlington Heights, IL, USA). The blot was reprobed 
with anti-actin antibody (I-19; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) to control loading variations.
Cell invasion assay
Cell migration was measured using a Transwell migration ap-
paratus (Costar Inc., Cambridge, UK) with minor modifica-
tion as described previously.9 The filters (8-µm pore size) 
were coated with 1% gelatin solution on both the top and bot-
tom surfaces. The cells from each group (si-KITENIN group, 
scrambled group) were harvested, washed once in serum-free 
sion and dissemination.1 Gene therapy for tumor metastasis 
is a promising because it inhibits the spread of cancer re-
gardless of the tumorigenicity.2,3
A large body of evidence suggests that down-regulation of 
KAI1/CD82 expression occurs with invasive and metastatic 
disease, and that it is an important step in the progression of 
many human malignancies.4-8 KAI1, a tumor metastasis 
suppressor gene, is a transmembrane glycoprotein that is a 
member of the tetraspanin superfamily. The metastasis sup-
pressor function was recently reported to be decreased in a 
spliced variant of KAI1 at the COOH-terminal region, sug-
gesting that the COOH-terminal region of KAI1 is impor-
tant for the effects of KAI1 on cell motility.9 Subsequently, a 
protein that interacted with the COOH-terminal cytoplasm 
domain of KAI1 was identified via a two-hybrid yeast sys-
tem.10 The function of this protein Vang-like 1 (VANGL111) 
during carcinogenesis has not been fully described, and it 
has been renamed as KAI1 COOH-terminal interacting tet-
raspanin (KITENIN). 
KITENIN-overexpressing CT-26 mouse colon cancer 
cells have shown increased tumorigenicity and early hepat-
ic metastasis in vivo, as well as increased invasiveness and 
adhesiveness to fibronectin in vitro, compared to parental 
cells.10 Moreover, the suppression of progression and me-
tastasis of established colon cancer has been observed in 
mice after intravenous delivery of small interfering RNA 
(siRNA) targeting KITENIN.12 
We recently reported that KITENIN promoted pulmo-
nary metastasis in a murine model of SCC by increasing 
cancer cell invasion and adhesion to fibronectin,13 and that 
KITENIN represented a more aggressive phenotype in a 
murine model of oral cavity squamous carcinoma.14 Fur-
thermore, we investigated the expression of KITENIN in 
human laryngeal SCC, and found that KITENIN expres-
sion was significantly increased in laryngeal cancer tissues, 
compared to the adjacent normal tissue mucosa, as well as 
in metastatic lymph nodes compared to non-metastatic 
lymph nodes. High KITENIN expression was associated 
significantly with an advanced disease stage, extent of the 
tumor, and lymph node metastasis.15
siRNA is a small double-stranded, non-protein coding 
RNA (21-31 nucleotides) involved in gene silencing func-
tions, especially RNA interference (RNAi). This ability of 
siRNA has provided researchers with a novel tool to block 
the expression of disease-causing genes, provided that their 
mRNA sequences are known. siRNAs can be delivered to 
cells either exogenously as synthetic agents or endogenously Gene Therapy Using KITENIN-Antisense
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RESULTS
           
Western blot analysis
Fig. 1 shows that KITENIN was strongly expressed in the 
SNU-1041 cells and scrambled DNA-transfected SNU-1041 
cells (SNU-1041/Scrambled). However, the expression of 
KITENIN protein was not observed in the si-KITENIN-
transfected SNU-1041 cells (SNU-1041/si-KITENIN), dem-
onstrating that KITENIN was effectively blocked by siRNA.
Cell invasion assay
As shown in Fig. 2, the number of invading si-KITENIN-
transfected SNU-1041 cells was 64.2±19.2, whereas the 
number of the scrambled DNA-transfected SNU-1041 cells 
DMEM/0.2% bovine serum albumin (BSA), and resuspend-
ed at 2×106 cells/µL DMEM/0.2% BSA. To start the assay, 
120 µL (2.4×105 cells) was loaded onto the upper chamber of 
the Transwell, whereas 400 µL DMEM/0.2% BSA contain-
ing 20 µg/mL human plasma fibronectin (Calbiochem, La 
Jolla, CA, USA), a chemotactic factor, was loaded onto the 
lower chamber. The Transwell apparatus was incubated for 24 
hours at 37°C. At the end of incubation, the cells attached to 
the membranes were fixed and stained with Diff-Quick (Inter-
national Reagents, Kobe, Japan) by following the manufac-
turer’s protocol. The cells on the top surface of the filters were 
wiped off with cotton balls, and the cells that migrated to the 
bottom surface were counted in ten random squares of 
0.5×0.5 mm2 by microscopic field of view. The results were 
expressed as mean±SE of the number of cells/field.
Cell migration assay
si-KITENIN-transfected and scrambled DNA-transfected 
SNU-1041 cells were seeded in a 6-well plate (1×105 cells/
well). Twenty-four hours later, the media were changed to 
serum-free DMEM and incubated for 12 hours. After the 
media were removed from the wells, a straight transverse 
line through the adherent cells was drawn using a ruler and 
a 1000 µL-tip, resulting in a uniform gap. The media were 
changed to DMEM supplemented with 2% fetal bovine se-
rum. At 0, 20, 28, and 44 hours later; the distances between 
the gaps were measured in centimeters after capture of six 
random sites by the microscopic field of view.
Cell proliferation assay
The proliferation and viability of the cells were measured 
using an enhanced cell viability assay kit, EZ CyTox (Daeil 
Lab Service Co., Seoul, Korea). The cells were seeded at 2 
×104 cells/well in 48-well plates, transfected with si-KIT-
ENIN and scrambled DNA, and grown overnight in the 
presence of serum. Next, EZ CyTox was added according 
to the manufacturer’s instructions for 2 hours, after which 
the discolored cells were moved into 96-well plates for 
analysis. Absorbance at 450 nm was determined using a 
microplate reader with SOFTmax PRO software (Molecu-
lar Devices, Sunnyvale, CA, USA).
 
Statistical analysis
Experimental differences were tested for statistical signifi-
cance with SPSS 16.0 (SPSS Inc., Chicago, IL, USA). The 
Student’s t-test was used, and p values of less than 0.05 
were considered statistically significant.
KITENIN
β-actin
SNU-1041 SNU-1041/si-KITENIN SNU-1041/Scrembled
Fig. 1. KITENIN expression in SNU-1041 cells: KITENIN was strongly ex-
pressed in SNU-1041 cells and scrambled DNA-transfected SNU-1041 cells 
(SNU-1041/Scrambled). The expression of KITENIN protein was not ob-
served in si-KITENIN-transfected SNU-1041 cells (SNU-1041/si-KITENIN).
Fig. 2. Cell invasion assay: the number of invading si-KITENIN-transfected 
SNU-1041 cells (A) was 64.2±19.2, whereas the number was 98.6±10.2 for 
the scrambled DNA-transfected SNU-1041 cells (B), as measured by 10 
random squares of 0.5×0.5 mm
2 on the microscopic field of view under con-
ditions with 20 µg/mL of fibronectin; the difference between the two groups 
was statistically significant (p<0.001)(C). 
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the control group as time passed by 20, 28, 44 hours, com-
pared to the si-KITENIN group (p<0.001)(Fig. 3). For the 
scrambled group, the gap was nearly filled within 44 hours, 
however, it remained wide open in the si-KITENIN group. 
Cell proliferation assay
The number of proliferating cells, as determined by absor-
bance, was significantly decreased in the si-KITENIN group 
compared to the scrambled group (Fig. 4). On the third day, 
absorbance was 0.4933±0.0484 in the si-KITENIN group, 
whereas 0.6023±0.0319 in the scrambled group (p<0.001). 
DISCUSSION
siRNA, known as RNAi, is a powerful tool for strong and 
specific suppression of gene expression.16 The use of these 
molecules can be applied to a wide range of cancers and oth-
er proliferative disorders where aberrant gene expression oc-
curs. Therefore, oncogenic and mutant tumor suppressor 
genes might represent potential targets for the RNAi ap-
proach. It has been shown that mutated p53 protein, involved 
in almost half of human malignancies, was eliminated by 
siRNA and the function of wild-type p53 restored.20 Other 
examples include: elimination of the Ras oncogene using 
siRNAs,21 transfection of leukemic cells with siRNAs target-
ing a BCR-ABL fusion transcript, thereby inducing apopto-
sis,22,23 and targeting of VEGF by siRNAs.24 
In this study, siRNA targeting KITENIN was effective. 
SNU-1041, an established human head and neck squamous 
carcinoma cell line,17-19 expressed very high levels of KIT-
was 98.6±10.2, as measured by 10 random squares of 0.5× 
0.5 mm2 by the microscopic field of view under conditions 
with 20 µg/mL of fibronectin; the difference between the 
two groups was statistically significant (p<0.001). 
Cell migration assay
The artificial wound gap became significantly narrower in 
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Fig. 3. Cell migration assay: the artificial wound gap became significantly 
narrower in the control group as time passed by 20, 28, 44 hours, compared 
to the si-KITENIN group (p<0.001)(B). In the scrambled group, the gap was 
nearly filled within 44 hours. However, it remained wide open in the si-KIT-
ENIN group (A). 
Fig. 4. Cell proliferation assay: the proliferating cells, as determined by ab-
sorbance, were significantly decreased in the si-KITENIN group compared 
to the scrambled group. On the third day, absorbance was 0.4933±0.0484 in 
the si-KITENIN group and 0.6023±0.0319 in the scrambled group (p<0.001). 
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ENIN, which functions as a metastasis-promoting gene. 
Our previous data demonstrated that many human head and 
neck squamous cancer tissues expressed KITENIN, and 
that the level of KITENIN correlated with the disease stage. 
After transfection of si-KITENIN into SNU-1041 cells, 
KITENIN was no longer identified in the cells. siRNA-
transfected SNU-1041 cells showed reduced in vitro inva-
sion, migration, and proliferative characteristics compared 
to the cells in the control group.
siRNAs can be delivered in two ways: exogenous admin-
istration of synthetic siRNAs and endogenous expression 
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we used the lipofectamine trasfection reagent (RNAiMAX, 
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gies may help or delay the progression (invasion, migration 
and proliferation) of head and neck squamous carcinoma.
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